U.S. Markets close in 4 hrs 20 mins

Pharming Group N.V. (PHGUF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.79000.0000 (0.00%)
As of 11:48AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7900 - 0.7900
52 Week Range0.7600 - 1.8500
Avg. Volume4,371
Market Cap508.036M
Beta (5Y Monthly)1.69
PE Ratio (TTM)13.62
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • TipRanks

    Buy These 2 Stocks Before They Jump Over 100%, Says Oppenheimer

    What happens when headwinds meet tailwinds? In meteorology, head-on collisions of opposite air masses gives birth to thunderstorms; add some Coriolis force, and the storm becomes cyclonic. As historian Bruce Catton once described such action, in a political context, ‘tornado weather: sultriest and most menacing.’ But it seems, for now, that we’ve missed that bullet. As Oppenheimer’s chief investment strategist John Stoltzfus writes, “While economic data continues to show persistently high levels

  • Zacks

    Pharming Group NV (PHGUF) to Report Q3 Results: What Awaits?

    Pharming Group NV (PHGUF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga

    Orchard Therapeutics, Pharming Ink Development Pact For Gene Therapy

    Orchard Therapeutics plc (NASDAQ: ORTX) and Pharming Group NV (NASDAQ: PHAR) have collaborated to research, develop, manufacture and commercialize OTL-105 for hereditary angioedema (HAE). OTL-105 is an investigational autologous hematopoietic stem cell (HSC) gene therapy designed to increase C1 esterase inhibitor (C1-INH) in HAE patient serum to prevent hereditary angioedema attacks. OTL-105 inserts one or more functional copies of the SERPING1 gene into patients' HSCs ex vivo, which are then tr